KT-413

· Kymera Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KT-413, covering 2024-12-10 to 2024-12-10. Get the full timeline:

Most recent: Clinical Trial Update: Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL [Phase 1]